Focused on solving unmet needs in ophthalmology
Our pipeline of topical drug candidates promises improvement in drug delivery for the back and front of the eye
OCS-01, OCS-03, OCS-04, OCS-05 are based on SNP technology while OCS-02 is based on single chain antibody fragment (scFv) against TNFα
OCS-01: A potential paradigm shift in DME treatment
Our most advanced product candidate, OCS-01, is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments and enhances their bioavailability in the relevant eye tissues. If approved in DME, it has the potential to provide a new option for patients.
OCS-01: A potential treatment for Post-cataract Surgery Inflammation
Because patients undergoing cataract surgery are usually on several medications daily, adding more eye drops can be challenging. A long-acting topical solution such as OCS-01 has the potential of reducing the frequency of the burden of administration to patients.
OCS-02: Potentially the first topical anti-TNF alpha therapy for ophthalmic indications
The compound, named OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including two controlled studies under IND. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye including Dry Eye Disease.